The DOI matches its Crossref record.
Polypharmacology in a Single Drug: Multitarget Drugs
Abstract
Polypharmacology offers a model for the way drug discovery must evolve to develop therapies most suited to treating currently incurable diseases. It is driven by a worldwide demand for safer, more effective, and affordable medicines against the most complex diseases, and by the failures of modern drug discovery to provide these. Polypharmacology can involve combinations and/or multitarget drugs (MTD). Although not mutually exclusive, my premise is that MTDs have inherent advantages over combinations. This review article focuses on MTDs from a medicinal chemistry perspective. I will explore their use in current clinical practice, their likely application in the future, and the challenges to be overcome to achieve this goal. Keywords: Multifactorial diseases, Combination therapy, multitarget drug discovery, network pharmacology, multitargetdirected ligands, designed multiple ligands
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Both are critical issues in AD: (a) adherence to a complex therapy is unlikely for forgetful AD patients and their caregivers; (b) coexistence of chronic disease, polypharmacy, and impaired organ functions makes geriatric population particularly susceptible to DDIs.49”
From From combinations to multitarget-directed ligands: A continuum in Alzheimer’s disease polypharmacology (2021) · cites this paper as [49]
In the citing paper
“Both are critical issues in AD: (a) adherence to a complex therapy is unlikely for forgetful AD patients and their caregivers; (b) coexistence of chronic disease, polypharmacy, and impaired organ functions makes geriatric population particularly susceptible to DDIs.49”
From From combinations to multitarget-directed ligands: A continuum in Alzheimer’s disease polypharmacology (2021) · cites this paper as [49]
In the citing paper
“Furthermore, the single-molecule pharmacokinetic profile of hybrids, from administration to secretion, may allow to avoid DDI, that occur more frequently in AD patients, because of the coexistence of chronic disease, therapies, and impaired organ functions.49”
From From combinations to multitarget-directed ligands: A continuum in Alzheimer’s disease polypharmacology (2021) · cites this paper as [49]
Citations
Cited by
Sorted by citations
A perspective on multi‐target drug discovery and design for complex diseases
Ramsay, R. R., Popović-Nikolić, M. R., Nikolic, K. M., Uliassi, E., & Bolognesi, M. L. (2018) · Clinical and Translational Medicine · doi:10.1186/s40169-017-0181-2 · Cited by 751
“In parallel, we have learned that molecules hitting more than one target may possess in principle a safer profile compared to single-targeted ones [1, 2].”
BackgroundSelf-citationPolypharmacology – Foe or Friend?
Peters, J. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm400856t · Cited by 485
Drug combination therapy increases successful drug repositioning
Sun, W., Sanderson, P. E. J., & Zheng, W. (2016) · Drug Discovery Today · doi:10.1016/j.drudis.2016.05.015 · Cited by 445
Molecular Hybridization as a Tool for Designing Multitarget Drug Candidates for Complex Diseases
Ivasiv, V., Albertini, C., Gonçalves, A. E., Rossi, M., & Bolognesi, M. L. (2019) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026619666190619115735 · Cited by 396
Self-citationPotential Impact of the Multi-Target Drug Approach in the Treatment of Some Complex Diseases
Makhoba, X. H., Viegas, C., Mosa, R. A., Viegas, F. P. D., & Pooe, O. J. (2020) · Drug Design Development and Therapy · doi:10.2147/dddt.s257494 · Cited by 337
Rational Design of Multitarget-Directed Ligands: Strategies and Emerging Paradigms
Zhou, J., Jiang, X., He, S., Jiang, H., Feng, F., Liu, W., Qu, W., & Sun, H. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b00017 · Cited by 310
A Perspective on Multi-target Drugs for Alzheimer’s Disease
Benek, O., Korabecny, J., & Soukup, O. (2020) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2020.04.008 · Cited by 260
Sulfonamide derivatives as multi-target agents for complex diseases
Apaydın, S., & Török, M. (2019) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2019.06.041 · Cited by 262
Albertini, C., Salerno, A., de Sena Murteira Pinheiro, P., & Bolognesi, M. L. (2021) · Medicinal Research Reviews · doi:10.1002/med.21699 · Cited by 179
Self-citationChronic Inflammatory Diseases, Anti-Inflammatory Agents and Their Delivery Nanosystems
Plachá, D., & Jampílek, J. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13010064 · Cited by 181
Nepovimová, E., Uliassi, E., Korábečný, J., Peña‐Altamira, E., Samez, S., Pesaresi, A., Garcia, G. E., Bartolini, M., Andrisano, V., Bergamini, C., et al. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm5010804 · Cited by 156
Self-citation2,3-Dihydroquinazolin-4(1 H )-one as a privileged scaffold in drug design
Badolato, M., Aiello, F., & Neamati, N. (2018) · RSC Advances · doi:10.1039/c8ra02827c · Cited by 144
Recent Progress on Tubulin Inhibitors with Dual Targeting Capabilities for Cancer Therapy
Wen, S., Wang, G., Zhang, Y., Bu, F., Zhang, S., Miller, D. D., Li, W., Ouyang, L., & Wang, Y. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00100 · Cited by 155
Gontijo, V. S., Viegas, F. P. D., Ortiz, C. J. C., Silva, M. D. F., Damásio, C. M., Rosa, M. C., Campos, T. G., Couto, D. S., Dias, K. S. T., & Viegas, C. (2019) · Current Neuropharmacology · doi:10.2174/1385272823666191021124443 · Cited by 151
“To date, approaches in drug design are still based in the reductionist concept of “one gene-one drug-one target”, leading to a linear model for a clinical effect, by which a single molecule binds selectively to a single molecular target resulting in a desired therapeutical response and undesired adverse effects [54-56…”
BackgroundCaffeic acid derivatives, analogs and applications: a patent review (2009 – 2013)
Silva, T., Oliveira, C., & Borges, F. (2014) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.2014.959492 · Cited by 132
“The exploration of this novel drug-design paradigm might result in the development of more efficient molecules [70,71].”
BackgroundAnti-cholinesterase hybrids as multi-target-directed ligands against Alzheimer’s disease (1998–2018)
Mishra, P., Kumar, A., & Panda, G. (2019) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2019.01.025 · Cited by 130
Advances in the treatment of Chagas disease: Promising new drugs, plants and targets
García‐Huertas, P., & Cardona-Castro, N. M. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.112020 · Cited by 126
Harnessing Polypharmacology with Medicinal Chemistry
Bolognesi, M. L. (2019) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.9b00039 · Cited by 128
Self-citationTacrine-resveratrol fused hybrids as multi-target-directed ligands against Alzheimer's disease
Jerábek, J., Uliassi, E., Guidotti, L., Korábečný, J., Soukup, O., Šepsová, V., Hrabinová, M., Kuča, K., Bartolini, M., Peña‐Altamira, E., et al. (2016) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2016.12.048 · Cited by 114
Self-citationPrati, F., Cavalli, A., & Bolognesi, M. (2016) · Molecules · doi:10.3390/molecules21040466 · Cited by 110
“Furthermore, simplifying the therapeutic regimen with a single multitarget agent could add significant value for dementia patients and their caregivers who have inherent difficulty with compliance and therapy adherence [8].”
BackgroundSelf-citationPolypharmacology: The Rise of Multitarget Drugs over Combination Therapies
Rosini, M. (2014) · Future Medicinal Chemistry · doi:10.4155/fmc.14.25 · Cited by 103
Wang, T., Liu, X.-H., Guan, J. Z., Ge, S., Wu, M., Lin, J., & Yang, L.-R. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.02.076 · Cited by 97
Rosini, M., Simoni, E., Minarini, A., & Melchiorre, C. (2014) · Neurochemical Research · doi:10.1007/s11064-014-1250-1 · Cited by 95
Pogodin, P. V., Lagunin, A. A., Filimonov, D. A., & Poroikov, V. (2015) · SAR and QSAR in environmental research · doi:10.1080/1062936x.2015.1078407 · Cited by 91
“Multi-target drug action is also con fi rmed in a number of publications [9 – 11] and by the DrugBank data [12], indicating that most drugs interact with two or more targets.”
BackgroundGunter, N. V., Teh, S. S., Lim, Y. M., & Mah, S. H. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.594202 · Cited by 91
“Thus, the concept of polypharmacology which aims to develop single drugs that recognize multiple molecular targets emerged rapidly as a popular strategy in drug design and development (Bolognesi, 2013; Makhoba et al., 2020).”
BackgroundÇınar, R., Gochuico, B. R., Iyer, M. R., Jourdan, T., Yokoyama, T., Park, J. K., Coffey, N. J., Pri‐Chen, H., Szanda, G., Liu, Z., et al. (2017) · JCI Insight · doi:10.1172/jci.insight.92281 · Cited by 92
“Polypharmacology is an emerging strategy that involves the use of a single chemical entity to target multiple therapeutic pathways (6).”
BackgroundZhang, K., Lai, F., Lin, S., Ji, M., Zhang, J., Zhang, Y., Jin, J., Fu, R., Wu, D., Tian, H., et al. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b00390 · Cited by 100
Çınar, R., Iyer, M. R., Liu, Z., Cao, Z., Jourdan, T., Erdélyi, K., Godlewski, G., Szanda, G., Liu, J., Park, J. K., et al. (2016) · JCI Insight · doi:10.1172/jci.insight.87336 · Cited by 86
“simultaneously hitting multiple therapeutic targets (2).”
Dias, K. S. T., de Paula, C. T., dos Santos, T., Souza, I. N. D. O., Boni, M. S., Guimarães, M. J. R., da Silva, F. M. R., Castro, N. G., Neves, G. A., Veloso, C. C., et al. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.02.043 · Cited by 83
Multitarget Strategies in Alzheimer’S Disease: Benefits and Challenges on the Road to Therapeutics
Rosini, M., Simoni, E., Caporaso, R., & Minarini, A. (2016) · Future Medicinal Chemistry · doi:10.4155/fmc-2016-0003 · Cited by 79
Prati, F., Uliassi, E., & Bolognesi, M. L. (2014) · MedChemComm · doi:10.1039/c4md00069b · Cited by 77
Self-citationViayna, E., Sabaté, R., & Muñoz‐Torrero, D. (2013) · Current Topics in Medicinal Chemistry · doi:10.2174/15680266113139990139 · Cited by 77
“…and the effectiveness of single-target therapies, and boosts the use of phenotypic in vivo tests and the development of multi-target therapies, particularly multi-target single-molecule drugs, i.e. the so-called multi-target drugs, multiple ligands or multi-target-directed ligands [40] [41].”
BackgroundPharmacological intervention of histone deacetylase enzymes in the neurodegenerative disorders
Gupta, R. V., Ambasta, R. K., & Kumar, P. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.117278 · Cited by 85
Gupta, P. S. S., Bhat, H. R., Biswal, S., & Rana, M. K. (2020) · Journal of Molecular Liquids · doi:10.1016/j.molliq.2020.114375 · Cited by 67
Polypharmacological drug actions of recently FDA approved antibiotics
Wetzel, C., Lonneman, M., & Wu, C. A. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112931 · Cited by 66
Polypharmacology of dopamine receptor ligands
Butini, S., Nikolic, K. M., Kassel, S., Brückmann, H., Filipić, S., Agbaba, D. D., Gemma, S., Brogi, S., Brindisi, M., Campiani, G., et al. (2016) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2016.03.011 · Cited by 69
Chandrika, S. K., Haixiao, J., Naman, C. B., & Sajeevan, T. P. (2020) · Drug Development Research · doi:10.1002/ddr.21673 · Cited by 67
Marine natural products for multi-targeted cancer treatment: A future insight
Kumar, M. S., & Adki, K. M. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.05.142 · Cited by 67
Synthesis and evaluation of novel dual BRD4/HDAC inhibitors
Amemiya, S., Yamaguchi, T., Hashimoto, Y., & Noguchi‐Yachide, T. (2017) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2017.04.043 · Cited by 65
Salinomycin and its derivatives – A new class of multiple-targeted “magic bullets”
Antoszczak, M., & Huczyński, A. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.05.031 · Cited by 63
Li, Y., Wang, P., Li, X. X., Yu, C. Y., Yang, H. J., Zhou, J., Xue, W., Tan, J., & Zhu, F. (2016) · PLoS ONE · doi:10.1371/journal.pone.0165737 · Cited by 59
“So far, several studies have been conducted to assess the applicability domain of both multi-target drug and combination product and to analyze their advantages over another [23,24].”
BackgroundA review on pharmacophoric designs of antiproliferative agents
Rana, A., Alex, J. M., Chauhan, M., Joshi, G., & Kumar, R. (2014) · Medicinal Chemistry Research · doi:10.1007/s00044-014-1196-5 · Cited by 58
“Various strategies have been adopted for combating above-mentioned problems via synergistic action and dose reduction involving either combining two pharmacophores, (2) using a dual pharmacophore in a single molecule, or (3) utilizing the multi-targeted pharmacophore approaches (Bolognesi, 2013).”
MethodKeri, R. S., Quintanova, C., Chaves, S., Silva, D. F., Cardoso, S. M., & Santos, M. A. (2015) · Chemical Biology & Drug Design · doi:10.1111/cbdd.12633 · Cited by 56
“Accordingly, the current drug strategy has been based on the development of anti-Alzheimer agents with multiple potencies (3,4), such as the inhibition of AChE and amyloid-beta (Ab) peptide aggregation as well as antioxidant activity.”
BackgroundDocking Studies for Multi-Target Drugs
Scotti, L., Mendonça, F. J. B., Ishiki, H. M., Ribeiro, F. F., Singla, R. K., Barbosa‐Filho, J. M., da Silva, M. S., & Scotti, L. (2015) · Current Drug Targets · doi:10.2174/1389450116666150825111818 · Cited by 58
Dual-target inhibitors based on acetylcholinesterase: Novel agents for Alzheimer's disease
Zhao, X., Hu, Q., Wang, X., Li, C., Chen, X., Zhao, D. H., Qiu, Y., Xu, H., Wang, J., Ren, L., et al. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116810 · Cited by 56
Doadrio, A. L., Sánchez-Montero, J. M., Doadrio, J. C., Salinas, A. J., & Vallet‐Regí, M. (2016) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2016.11.002 · Cited by 55
“Thus, medications containing several active components in a single dose (Bender et al., 2006; Bolognesi, 2013; Petrelli and Valabrega, 2009) that for hypertension treatment is called polypill (Lonn et al., 2010; Sleight et al., 2006; TIP Study, 2009).”
BackgroundRecent Advances in the Rational Drug Design Based on Multi-target Ligands
Yang, T., Sui, X., Yu, B., Shen, Y., & Cong, H. (2020) · Current Medicinal Chemistry · doi:10.2174/0929867327666200102120652 · Cited by 55
What are the challenges with multi-targeted drug design for complex diseases?
Zięba, A., Stępnicki, P., Matosiuk, D., & Kaczor, A. A. (2022) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2022.2072827 · Cited by 57
Belluti, F., Uliassi, E., Veronesi, G., Bergamini, C., Kaiser, M., Brun, R., Viola, A., Fato, R., Michels, P. A. M., Krauth‐Siegel, R. L., et al. (2014) · ChemMedChem · doi:10.1002/cmdc.201300399 · Cited by 53
Self-citationNew Approaches to Treating Alzheimer's Disease
Zheng, H., Fridkin, M., & Youdim, M. B. H. (2015) · Perspectives in Medicinal Chemistry · doi:10.4137/pmc.s13210 · Cited by 52
2-Phenoxy-1,4-naphthoquinones: From a Multitarget Antitrypanosomal to a Potential Antitumor Profile
Prati, F., Bergamini, C., Molina, M. T., et al. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b00748 · Cited by 49
Self-citationHajjo, R., Sabbah, D. A., Abusara, O. H., & Bawab, A. Q. A. (2022) · Diagnostics · doi:10.3390/diagnostics12122975 · Cited by 57
Peña‐Altamira, E., Petralla, S., Massenzio, F., Virgili, M., Bolognesi, M. L., & Monti, B. (2017) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2017.00175 · Cited by 46
“Considering the multifactorial nature of cognitive impairment in aging, especially in AD, it is evident that a multitarget-based approach is essential to address this complex condition (Bolognesi, 2013).”
BackgroundSelf-citationMangiatordi, G. F., Intranuovo, F., Delre, P., Abatematteo, F. S., Abate, C., Niso, M., Creanza, T. M., Ancona, N., Stefanachi, A., & Contino, M. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c01357 · Cited by 49
Plazas, E., Casoti, R., Murillo, M. C. Á., Costa, F. B. D., & Suárez, L. E. C. (2019) · Phytochemistry · doi:10.1016/j.phytochem.2019.112128 · Cited by 46
Detecting similar binding pockets to enable systems polypharmacology
Duran‐Frigola, M., Siragusa, L., Ruppin, E., Barril, X., Cruciani, G., & Aloy, P. (2017) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1005522 · Cited by 41
Rosado-Solano, D. N., Barón-Rodríguez, M. A., Sanabria, P., Parada, L. K. L., Galvis, C. E. P., Zorro-González, A. F., Kouznetsov, V. V., & Vargas-Méndez, L. Y. (2019) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.9b01067 · Cited by 44
Recent advances in multitarget-directed ligands targeting G-protein-coupled receptors
Ma, H., Huang, B., & Zhang, Y. (2020) · Drug Discovery Today · doi:10.1016/j.drudis.2020.07.004 · Cited by 43
“For these complex diseases, acting on a single target might be inadequate to achieve satisfactory therapeutic effects [8,9].”
BackgroundPrajapati, R., Seong, S. H., Park, S. E., Paudel, P., Jung, H. A., & Choi, J. S. (2021) · Scientific Reports · doi:10.1038/s41598-021-02843-6 · Cited by 44
Wu, S., Huang, Y., Wang, T., Li, K., Lu, J., Huang, M., Dong, G., & Sheng, C. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c02026 · Cited by 49
Quintanova, C., Keri, R. S., Marques, S. M., G-Fernandes, M., Cardoso, S. M., Serralheiro, M. L., & Santos, M. A. (2015) · MedChemComm · doi:10.1039/c5md00236b · Cited by 40
Pérez-Areales, F. J., Turcu, A. L., Barniol‐Xicota, M., Pont, C., Pivetta, D., Espargaró, A., Bartolini, M., Simone, A. D., Andrisano, V., Pérez, B., et al. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.07.051 · Cited by 44
“Even though the design and development of multitarget drugs can be very challenging [12], it has some clear advantages over multiple-medication therapies, such as simpler dose regimens and improved patient compliance, simpler pharmacokinetics and lack of drug‒drug interactions, and simpler clinical development, among…”
Thioamides in medicinal chemistry and as small molecule therapeutic agents
Huang, G., Cierpicki, T., & Grembecka, J. E. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116732 · Cited by 38
Recent progress on curcumin-based therapeutics: a patent review (2012-2016). Part I: Curcumin
Martino, R. M. C. D., Luppi, B., Bisi, A., Gobbi, S., Rampa, A., Abruzzo, A., & Belluti, F. (2016) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2017.1276566 · Cited by 36
“Drug combinations, based on the coadministration of two or more drugs acting by common or different mechanisms of action, allowed obtaining additive or synergistic therapeutic effects [29-31].”
BackgroundAntiviral drug discovery and development: challenges and future directions
Du, S., Hu, X., Li, P., Xu, S., Kim, M., Liu, X., & Zhan, P. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02539-7 · Cited by 41
Human Disease and Drug Pharmacology, Complex as Real Life
Viayna, E., Sola, I., Pietro, O. D., & Muñoz‐Torrero, D. (2013) · Current Medicinal Chemistry · doi:10.2174/0929867311320130002 · Cited by 36
“These strategies will be only briefly discussed herein, as they will be presented in more detail in other articles of this issue [94-104].”
BackgroundSimone, A. D., Russo, D., Ruda, G. F., Micoli, A., Ferraro, M., Martino, R. M. C. D., Ottonello, G., Summa, M., Armirotti, A., Bandiera, T., et al. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b01578 · Cited by 35
Drug Development for Alzheimer’s and Parkinson’s Disease: Where Do We Go Now?
Sequeira, L., Benfeito, S., Fernandes, C., Gaspar, A., Lima, I., Peixoto, J., Alves, C., Machado, C. S., Borges, F., & Chavarria, D. (2024) · Pharmaceutics · doi:10.3390/pharmaceutics16060708 · Cited by 37
“Therefore, drugs that can simultaneously manipulate multiple targets may provide therapeutic benefits in AD and PD diseases due to their multifactorial nature and complexity [296].”
BackgroundRecent advances in dopamine D 2 receptor ligands in the treatment of neuropsychiatric disorders
Jůza, R., Musílek, K., Mezeiová, E., Soukup, O., & Korábečný, J. (2022) · Medicinal Research Reviews · doi:10.1002/med.21923 · Cited by 34
Farag, A. K., Hassan, A. H. E., Jeong, H., Kwon, Y., Choi, J. G., Oh, M. S., Park, K. D., Kim, Y. K., & Roh, E. J. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.10.057 · Cited by 34
Dual Targeting Strategies on Histone Deacetylase 6 (HDAC6) and Heat Shock Protein 90 (Hsp90)
Bonanni, D., Citarella, A., Moi, D., Pinzi, L., Bergamini, E., & Rastelli, G. (2021) · Current Medicinal Chemistry · doi:10.2174/0929867328666210902145102 · Cited by 33
Rosini, M., Simoni, E., Bartolini, M., Soriano, E., Marco, J. L., Andrisano, V., Monti, B., Windisch, M., Hutter‐Paier, B., McClymont, D. W., et al. (2013) · ChemMedChem · doi:10.1002/cmdc.201300263 · Cited by 31
Self-citationEpidermal growth factor receptor dual-target inhibitors as a novel therapy for cancer: A review
Wang, C., Zhang, Y., Zhang, T., Xu, J., Yan, S., Liang, B., & Xing, D. (2023) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2023.127440 · Cited by 31
Berishvili, V. P., Voronkov, A. E., Radchenko, E. V., & Palyulin, V. A. (2018) · Molecular Informatics · doi:10.1002/minf.201800030 · Cited by 32
Multi-Target β-Protease Inhibitors from Andrographis paniculata: In Silico and In Vitro Studies
Panche, A. N., Chandra, S., & Diwan, A. (2019) · Plants · doi:10.3390/plants8070231 · Cited by 30
Mangione, W., & Samudrala, R. (2019) · Molecules · doi:10.3390/molecules24010167 · Cited by 25
“Coupling this with the finding that there 209 is a minimum number of proteins required to reach optimal benchmarking accuracies (Figure 2), which 210 was also observed by us previously [15,16], drugs should realistically be described in the context of 211 their multitarget nature, treating both small molecule compound…”
BackgroundMulti-targeted drug design strategies for the treatment of schizophrenia
Stępnicki, P., Kondej, M., Koszła, O., Żuk, J., & Kaczor, A. A. (2020) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2020.1816962 · Cited by 33
Feng, F., Zhang, W., Chai, Y., Guo, D., & Chen, X. (2022) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2022.115107 · Cited by 31
Castro, M. A., Gamito, A. M., Tangarife-Castaño, V. J., Roa-Linares, V. C., del Corral, J. M. M., Mesa-Arango, A. C., Betancur-Galvis, L. A., Francesch, A., & Feliciano, A. S. (2014) · RSC Advances · doi:10.1039/c4ra11726c · Cited by 28
Systematic Investigation of Dual-Target-Directed Ligands
Lembo, V., & Bottegoni, G. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c00838 · Cited by 32
Pravin, N., & Jóźwiak, K. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23116085 · Cited by 34
Prati, F., Bartolini, M., Simoni, E., Simone, A. D., Pinto, A., Andrisano, V., & Bolognesi, M. L. (2013) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2013.09.091 · Cited by 27
Self-citationCanale, V., Grychowska, K., Kurczab, R., Ryng, M., Keeri, A. R., Satała, G., Olejarz‐Maciej, A., Koczurkiewicz, P., Drop, M., Blicharz-Futera, K., et al. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112765 · Cited by 28
In vitro activity of non-antibiotic drugs against Staphylococcus aureus clinical strains
Boyd, N. K., Lee, G. C., Teng, C., & Frei, C. R. (2021) · Journal of Global Antimicrobial Resistance · doi:10.1016/j.jgar.2021.09.003 · Cited by 24
Zhu, C., Yang, Y., Li, X., Chen, X., Lin, X., & Wu, X. (2022) · Nano Research · doi:10.1007/s12274-021-4066-8 · Cited by 26
cando.py: Open Source Software for Predictive Bioanalytics of Large Scale Drug–Protein–Disease Data
Mangione, W., Falls, Z., Chopra, G., & Samudrala, R. (2020) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.0c00110 · Cited by 25
Bottegoni, G., Veronesi, M., Bisignano, P., Kacker, P., Favia, A. D., & Cavalli, A. (2015) · ChemMedChem · doi:10.1002/cmdc.201500521 · Cited by 25
Pasieka, A., Panek, D., Jończyk, J., Godyń, J., Szałaj, N., Latacz, G., Tabor, J., Mezeiová, E., Chantegreil, F., Dias, J., et al. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113397 · Cited by 30
De novo generation of dual-target ligands using adversarial training and reinforcement learning
Lu, F., Li, M., Min, X., Li, C., & Zeng, X. (2021) · Briefings in Bioinformatics · doi:10.1093/bib/bbab333 · Cited by 28
Gilberg, E., Gütschow, M., & Bajorath, J. (2019) · ACS Omega · doi:10.1021/acsomega.8b03481 · Cited by 26
Zajdel, P., Grychowska, K., Mogilski, S., Kurczab, R., Satała, G., Bugno, R., Kos, T., Gołębiowska, J., Malikowska‐Racia, N., Nikiforuk, A., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00224 · Cited by 28
“26,27 The molecular framework for developing compounds that target both receptors arises from the structural similarity of pyrroloquinoxaline I , a 5-HT 3 R ligand, 28 and CPPQ, a pyrroloquinoline-based 5-HT 6 R antagonist (Figure 2).”
Simone, A. D., Bartolini, M., Baschieri, A., Apperley, K. Y.-P., Chen, H. H., Guardigni, M., Montanari, S., Kobrlová, T., Soukup, O., Valgimigli, L., et al. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.07.058 · Cited by 25
Blaschke, T., Miljković, F. N., & Bajorath, J. (2019) · ACS Omega · doi:10.1021/acsomega.9b00492 · Cited by 22
Identifying Promiscuous Compounds with Activity against Different Target Classes
Feldmann, C., Miljković, F. N., Yonchev, D., & Bajorath, J. (2019) · Molecules · doi:10.3390/molecules24224185 · Cited by 27
Mondal, S., Vashi, Y., Ghosh, P., Roy, D., Barthakur, M., Kumar, S., & Iyer, P. K. (2020) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.0c00387 · Cited by 22
Genovese, M., Imperatore, C., Casertano, M., Aiello, A., Balestri, F., Piazza, L., Menna, M., CORSO, A. D., & Paoli, P. (2021) · Marine Drugs · doi:10.3390/md19100535 · Cited by 24
Combined drug triads for synergic neuroprotection in retinal degeneration
Maneu, V., Lax, P., de Diego, A. M. G., Cuenca, N., & de Diego, A. M. G. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.112911 · Cited by 23
Tang, H., Liang, Y., Shen, H., Cai, S., Yu, M., Fan, H., Ding, K., & Wang, Y. (2022) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2022.106112 · Cited by 27
One Drug for Multiple Targets: A Computational Perspective
Méndez‐Lucio, O., Naveja, J. J., Vite‐Caritino, H., Prieto-Martínez, F. D., & Medina‐Franco, J. L. (2017) · Journal of the Mexican Chemical Society · doi:10.29356/jmcs.v60i3.100 · Cited by 36
Design, synthesis and biological evaluation of novel c-Met/HDAC dual inhibitors
Dong, Y., Hu, H., Sun, Y., Qin, M., Gong, P., Hou, Y., & Zhao, Y. (2020) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2020.127610 · Cited by 22
Metadata
- Authors
- L. Bolognesi, M.
- Venue
- Current Medicinal Chemistry
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2013-03-01
- Volume
- 20
- Issue
- 13
- Pages
- 1639-1645
- ISSN
- 0929-8673 (ISSN-L)
- OpenAlex
- W2329046360
- Cited by
- 230
- References
- 0
- Citations by year
- 2026: 15 · 2025: 7 · 2024: 23 · 2023: 11 · 2022: 27 · 2021: 23 · 2020: 35 · 2019: 19 · 2018: 12 · 2017: 16 · 2016: 13 · 2015: 13 · 2014: 9 · 2013: 7
- FWCI
- 16.79
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Current Medicinal Chemistry (publishedVersion)
- PubMed (publishedVersion)
- Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna) (submittedVersion)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
- Keywords
- polypharmacology, multi-target drugs, multi-target drug discovery, combination therapy, network pharmacology, multi-target-directed ligands, complex diseases
- MeSH terms
- Animals, Drug Combinations, Drug Resistance, Microbial, Pharmaceutical Preparations, Humans, Drug Discovery
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
